DURECT Corporation (DRRX)
NASDAQ: DRRX · IEX Real-Time Price · USD
0.931
+0.015 (1.68%)
At close: Apr 26, 2024, 4:00 PM
0.914
-0.017 (-1.86%)
After-hours: Apr 26, 2024, 5:27 PM EDT
DURECT Revenue
In the year 2023, DURECT had annual revenue of $8.55M, a decrease of -55.67%. Revenue in the quarter ending December 31, 2023 was $2.67M, a -19.49% decrease year-over-year.
Revenue (ttm)
$8.55M
Revenue Growth
-55.67%
P/S Ratio
3.38
Revenue / Employee
$147,379
Employees
58
Market Cap
28.90M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.55M | -10.74M | -55.67% |
Dec 31, 2022 | 19.28M | 5.31M | 37.96% |
Dec 31, 2021 | 13.98M | -16.13M | -53.58% |
Dec 31, 2020 | 30.11M | 5.04M | 20.09% |
Dec 31, 2019 | 25.07M | 9.80M | 64.15% |
Dec 31, 2018 | 15.28M | -33.90M | -68.93% |
Dec 31, 2017 | 49.17M | 35.15M | 250.59% |
Dec 31, 2016 | 14.03M | -5.10M | -26.66% |
Dec 31, 2015 | 19.12M | -277.00K | -1.43% |
Dec 31, 2014 | 19.40M | 4.08M | 26.59% |
Dec 31, 2013 | 15.33M | -37.74M | -71.12% |
Dec 31, 2012 | 53.07M | 19.58M | 58.48% |
Dec 31, 2011 | 33.49M | 1.90M | 6.00% |
Dec 31, 2010 | 31.59M | 7.13M | 29.15% |
Dec 31, 2009 | 24.46M | -4.08M | -14.28% |
Dec 31, 2008 | 28.54M | -2.14M | -6.98% |
Dec 31, 2007 | 30.68M | 8.78M | 40.11% |
Dec 31, 2006 | 21.89M | -6.68M | -23.37% |
Dec 31, 2005 | 28.57M | 14.72M | 106.24% |
Dec 31, 2004 | 13.85M | 2.02M | 17.05% |
Dec 31, 2003 | 11.84M | 4.65M | 64.72% |
Dec 31, 2002 | 7.19M | 661.00K | 10.13% |
Dec 31, 2001 | 6.52M | 3.37M | 106.78% |
Dec 31, 2000 | 3.16M | 3.07M | 3,568.60% |
Dec 31, 1999 | 86.00K | - | - |
Dec 31, 1998 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Palatin Technologies | 7.10M |
Singular Genomics Systems | 2.91M |
NeuroOne Medical Technologies | 2.82M |
IGC Pharma | 1.22M |
Femasys | 1.07M |
Lexaria Bioscience | 386.00K |
DRRX News
- 4 weeks ago - DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update - PRNewsWire
- 7 weeks ago - DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada - PRNewsWire
- 2 months ago - DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - PRNewsWire
- 4 months ago - Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI) - Benzinga
- 5 months ago - DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - PRNewsWire
- 6 months ago - DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update - PRNewsWire
- 6 months ago - DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality - PRNewsWire